Artemisinin and its derivatives: a promising cancer therapy.
Artemisinin
Cancer
Cell lines
Combination therapy
Flavonoids
Transgenics
Journal
Molecular biology reports
ISSN: 1573-4978
Titre abrégé: Mol Biol Rep
Pays: Netherlands
ID NLM: 0403234
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
09
04
2020
accepted:
15
07
2020
pubmed:
28
7
2020
medline:
27
5
2021
entrez:
26
7
2020
Statut:
ppublish
Résumé
The world is experiencing a cancer epidemic and an increase in the prevalence of the disease. Cancer remains a major killer, accounting for more than half a million deaths annually. There is a wide range of natural products that have the potential to treat this disease. One of these products is artemisinin; a natural product from Artemisia plant. The Nobel Prize for Medicine was awarded in 2015 for the discovery of artemisinin in recognition of the drug's efficacy. Artemisinin produces highly reactive free radicals by the breakdown of two oxygen atoms that kill cancerous cells. These cells sequester iron and accumulate as much as 1000 times in comparison with normal cells. Generally, chemotherapy is toxic to both cancerous cells and normal cells, while no significant cytotoxicity from artemisinin to normal cells has been found in more than 4000 case studies, which makes it far different than conventional chemotherapy. The pleiotropic response of artemisinin in cancer cells is responsible for growth inhibition by multiple ways including inhibition of angiogenesis, apoptosis, cell cycle arrest, disruption of cell migration, and modulation of nuclear receptor responsiveness. It is very encouraging that artemisinin and its derivatives are anticipated to be a novel class of broad-spectrum antitumor agents based on efficacy and safety. This review aims to highlight these achievements and propose potential strategies to develop artemisinin and its derivatives as a new class of cancer therapeutic agents.
Identifiants
pubmed: 32710388
doi: 10.1007/s11033-020-05669-z
pii: 10.1007/s11033-020-05669-z
doi:
Substances chimiques
Antineoplastic Agents
0
Artemisinins
0
artemisinin
9RMU91N5K2
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
6321-6336Références
WHO (2008) Cancer statistics. WHO, Geneva
Hsiao WLW, Liu L (2010) The role of traditional Chinese herbal medicines in cancer therapy from TCM theory to mechanistic insights. Planta Med 76(11):1118–1131
pubmed: 20635308
Hanahan D, Weinberg RA (2011) The hallmarks of cancer: the next generation. Cell 144:646–674
doi: 10.1016/j.cell.2011.02.013
pubmed: 21376230
Efferth T, Dunstan H, Sauerbrey A, Miyachi H, Chitambar C et al (2001) The anti-malarial artesunate is also active against cancer. Int J Oncol 18:767–773
pubmed: 11251172
Efferth T, Saverbrey A, Olbrich A et al (2003) Molecular modes of action of artesunate in tumour cell lines. Mol Pharmacol 64(2):382–394
pubmed: 12869643
Efferth T (2003) Molecular modes of action of artesunate in tumor cell lines. Mol Pharmacol 64(2):382–394
pubmed: 12869643
Efferth T, Sauerbrey A, Olbrich A, Gebhart E, Rauch P, Weber HO et al (2003) Molecular modes of action of artesunate in tumor cell lines. Mol Pharmacol 64:382–394
pubmed: 12869643
Reungpatthanaphong P, Mankhetkorn S (2002) Modulation of multidrug resistance by artemisinin, artesunate and dihydroartemisinin in K562/adr and GLC4/adr resistant cell lines. Biol Pharm Bull 25(12):1555–1561
pubmed: 12499639
Woerdenbag HJ, Moskal TA, Pras N et al (1993) Cytotoxicity of artemisinin-related endoperoxides to Ehrlich ascites tumor cells. J Nat Prod 56(6):849–856
pubmed: 8350087
Dondorp AM, Nosten F, Yi P et al (2009) Artemisinin resistance in Plasmodium falciparum malaria. New Engl J Med 361(5):455–467
pubmed: 19641202
Gordi T, Lepist EI (2004) Artemisinin derivatives: toxic for laboratory animals, safe for humans? Toxicol Lett 147(2):99–107
pubmed: 14757313
Abad MJ, Bedoya LM, Apaza L, Bermejo P (2012) The Artemisia L. genus: a review of bioactive essential oils. Molecules 17(3):2542–2566
pubmed: 22388966
pmcid: 6268508
Bora KS, Sharma A (2011) The genus Artemisia: a comprehensive review. Pharm Biol 49(1):101–109
pubmed: 20681755
Sadiq A, Hayat MQ, Ashraf M (2014) Ethnopharmacology of Artemisia annua L.: A review. Artemisia annua-pharmacology and biotechnology. Springer, Cham, pp 9–25
Lubbe A, Seibert I, Klimkait T, Van der Kooy F (2012) Ethnopharmacology in overdrive: the remarkable anti-HIV activity of Artemisia annua. J Ethnopharmacol 141(3):854–859
pubmed: 22465592
Lee SK, Kim H, Park J, Kim H-J, Kim KR, Son SH et al (2017) Artemisia annua extract prevents ovariectomy-induced bone loss by blocking receptor activator of nuclear factor kappa-B ligand-induced differentiation of osteoclasts. Sci Rep 7(1):17332
pubmed: 29230013
pmcid: 5725529
Li X, Ba Q, Liu Y, Yue Q, Chen P, Li J et al (2017) Dihydroartemisinin selectively inhibits PDGFRα-positive ovarian cancer growth and metastasis through inducing degradation of PDGFRα protein. Cell Discov 3:17042
pubmed: 29387451
pmcid: 5787695
Feng M-X, Hong J-X, Wang Q, Fan Y-Y, Yuan C-T, Lei X-H et al (2016) Dihydroartemisinin prevents breast cancer-induced osteolysis via inhibiting both breast cancer cells and osteoclasts. Sci Rep 6:19074
pubmed: 26743690
pmcid: 4705478
Chen H, Sun B, Pan S, Jiang H, Sun X et al (2009) Dihydroartemisinin inhibits growth of pancreatic cancer cells in vitro and in vivo. Anticancer Drugs 20:131–140
pubmed: 19209030
Chen T, Li M, Zhang R, Wang H et al (2009) Dihydroartemisinin induces apoptosis and sensitizes human ovarian cancer cells to carboplatin therapy. J Cell Mol Med 13(7):1358–1370
pubmed: 18466355
Kim SJ, Kim MS, Lee JW, Lee CH, Yoo H, Shin SH et al (2006) Dihydroartemisinin enhances radio sensitivity of human glioma cells in vitro. J Cancer Res Clin Oncol 132:129–135
pubmed: 16273420
Lu JJ, Chen S, Zhang M, Ding XW, Meng LH et al (2011) The anti-cancer activity of dihydroartemisinin is associated with induction of iron-dependent endoplasmic reticulum stress in colorectal carcinoma HCT116 cells. Invest New Drugs 29:1276–1283
pubmed: 20607588
Mu D, Chen W, Yu B, Zhang C, Zhang Y, Qi H et al (2008) Calcium and survivin are involved in the induction of apoptosis by dihydroartemisinin in human lung cancer SPC-A-1 cells. Methods Find Exp Clin Pharmacol 29:33–38
Singh NP, Lai H (2001) Selective toxicity of dihydroartemisinin and holotransferrin toward human breast cancer cells. Life Sci 70:49–56
pubmed: 11764006
Zhang Y, Xu G, Zhang S, Wang D, Prabha PS, Zuo Z (2018) Antitumor research on artemisinin and its bioactive derivatives. Nat Prod Bioprospect 8(4):303–319
pubmed: 29633188
pmcid: 6102173
Roth RJ, Acton N (1989) The isolation of sesquiterpenes from Artemisia annua. J Chem Educ 66:349–350
Brown TA (1993) Gene cloning and DNA analysis and introduction. In: Brown TA (ed), Blackwell Science, pp 139–144
Nam W, Tak J, Ryu JK, Jung M, Yook JI, Kim HJ et al (2007) Effects of artemisinin and its derivatives on growth inhibition andapoptosis of oral cancer cells. Head Neck 29:335–340
pubmed: 17163469
Posner GH, McRiner AJ, Paik IH, Sur S, Borstnik K, Xie S, Shapiro TA, Alagbala A, Foster B et al (2004) Anticancer and antimalarial efficacy and safety of artemisinin-derived trioxane dimers in rodents. J Med Chem 47:1299–1302
pubmed: 14971910
Singh NP, Lai H (2004) Artemisinin induces apoptosis in human cancer cells. Anticancer Res 24:2277–2280
pubmed: 15330172
Thomas E, Axel S, Armin O, Erich G, Pia R, Oliver W et al (2003) Molecular modes of action of artesunate in tumor cell lines. Mol Pharmacol 64:382–394
Wu GD, Zhou HJ, Wu XH et al (2006) Apoptosis of human umbilical vein endothelial cells induced by artesunate. Vasc Pharmacol 41(6):205–212
Chen HH, Zhou HJ, Wu GD, Lou XE et al (2004) Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/flk-1. Pharmacology 71:1–9
pubmed: 15051917
Yamachika E, Habte T, Oda D et al (2004) Artemisinin: an alternative treatment for oral squamous cell carcinoma. Anticancer Res 24:2153–2160
pubmed: 15330155
Jiao Y, Ge C, Meng Q, Cao J, Tong J, Fan S et al (2007) Dihydroartemisinin is an inhibitor of ovarian cancer cell growth. Acta Pharmacol Sin 28(7):1045–1056. https://doi.org/10.1111/j.1745-7254.2007.00612.x
doi: 10.1111/j.1745-7254.2007.00612.x
pubmed: 17588342
Disbrow GL, Baege AC, Kierpiec KA et al (2005) Dihydroartemisinin is Cytotoxic to papillomavirus-expressing epithelial cells in vitro and in vivo. Cancer Res 65:10854–10861
pubmed: 16322232
Wu JM, Shan F, Wu GS, Li Y, Ding J, Xiao D, Han JX, Atassi G, Leonce S, Caignard DH, Renard P et al (2001) Synthesis and cytotoxicity of artemisinin derivatives containing cyanoarylmethyl group. Eur J Med Chem 36:469–479
pubmed: 11451535
Efferth T, Olbrich A, Bauer R et al (2002) mRNA expression profiles for the response of human tumor cell lines to the antimalarial drugs artesunate, arteether, and artemether. Biochem Pharmacol 64(4):617–623
pubmed: 12167480
Sadava D, Phillips T, Lin C, Kane SE et al (2002) Transferrin overcomes drug resistance to artemisinin in human small-cell lung carcinoma cells. Cancer Lett 179:151–156
pubmed: 11888669
Efferth T, Benakis A, Romero MR, Tomicic M, Rauh R, Steinbach D et al (2004) Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron. Free Radic Biol Med 37:998–1009
pubmed: 15336316
Efferth T (2004) Combination treatment of glioblastoma multiforme cell lines with the anti-malarial artesunate and the epidermal growth factor receptor tyrosine kinase inhibitor OSI-774. Biochem Pharmacol 67(9):1689–1700
pubmed: 15081868
Firestone GL, Sundar SN (2009) Anticancer activities of artemisinin and its bioactive derivatives. Expert Rev Mol Med 11:32
O’Neill PM, Barton VE, Ward SA et al (2010) The molecular mechanism of action of artemisinin–the debate continues. Molecules 15:1705–1721
pubmed: 20336009
pmcid: 6257357
Henry L, Tomikazu S, Narendra PS et al (2005) Oncologic, endocrine and metabolic treatment of cancer with artemisinin and artemisinin tagged iron-carrying compounds. Expert Opin Ther Targets 9(5):995–1007
Rowen RJ (2002) Artemisinin: from malaria to cancer treatment. Townsend Lett Doct Patients 86–88
Gong Y, Gallis BM, Goodlett DR, Yang Y, Lu H, Lacoste E et al (2013) Effects of transferrin conjugates of artemisinin and artemisinin dimer on breast cancer cell lines. Anticancer Res 33:123–132
pubmed: 23267137
Krishna S, Bustamante L, Haynes RK, Staines HM et al (2008) Artemisinins: their growing importance in medicine. Trends Pharmacol Sci 29:520–527. https://doi.org/10.1016/j.tips.2008.07.004
doi: 10.1016/j.tips.2008.07.004
pubmed: 18752857
pmcid: 2758403
Paik IH, Xie S, Shapiro TA, Labonte T, Narducci Sarjeant AA, Baege AC et al (2006) Second generation, orally active, antimalarial, artemisinin-derived trioxane dimers with high stability, efficacy, and anticancer activity. JMedChem 49:2731–2734
Sertel S, Plinkert P, Efferth T et al (2013) Activity of artemisinin-type compounds against cancer cells. In: Wagner H, Ulrich-Merzenich G (eds) Evidence and rational based research on chinese drugs. Springer, Vienna, pp 333–362
Stockwin LH, Han B, Yu SX, Hollingshead MG, ElSohly MA, Gul W et al (2009) Artemisinin dimer anticancer activity correlates with heme-catalyzed reactive oxygen species generation and endoplasmic reticulum stress induction. Int J Cancer 125:1266–1275
pubmed: 19533749
pmcid: 2752979
Yoon MK, Mitrea DM, Ou L, Kriwacki RW et al (2012) Cell cycle regulation by the intrinsically disordered proteins p21 and p27. Biochem Soc Trans 40:981–988
pubmed: 22988851
pmcid: 7065656
Tin AS, Sundar SN, Tran KQ, Park AH, Poindexter KM, Firestone GL et al (2012) Antiproliferative effects of artemisinin on human breast cancer cells requires the downregulated expression of the E2F1 transcription factor and loss of E2F1-target cell cycle genes. Anticancer Drugs 23:370–379
pubmed: 22185819
Chen G, Gong R, Shi X, Yang D, Zhang G et al (2016) Halofuginone and artemisinin synergistically arrest cancer cells at the G1/G0 phase by upregulating p21Cip1 and p27Kip1. Oncotarget 7(31):50302–50314
pubmed: 27385212
pmcid: 5226584
Huang Z, Huang X, Jiang D, Zhang Y, Huang B, Luo G et al (2016) Dihydroartemisinin inhibits cell proliferation by induced G1 arrest and apoptosis in human nasopharyngeal carcinoma cells. J Cancer Res Ther 12(1):244–247. https://doi.org/10.4103/0973-1482.151855
doi: 10.4103/0973-1482.151855
pubmed: 27072245
Tong Y, Tong Y, Liu Y, Zheng H, Zheng L, Liu W, Wu J, Ou R, Zhang G, Li F, Hu M, Liu Z, Lu L et al (2016) Artemisinin and its derivatives can significantly inhibit lung tumorigenesis and tumor metastasis through Wnt/β-catenin signaling. Oncotarget 7(21):31413–31428
pubmed: 27119499
pmcid: 5058767
Hou J, Wang D, Zhang R, Wang H et al (2008) Experimental therapy of hepatoma with artemisinin and Its derivatives: In vitro and in vivo activity, chemosensitization, and mechanisms of action. Clin Cancer Res 14(17):5519–5530. https://doi.org/10.1158/1078-0432.CCR-08-0197
doi: 10.1158/1078-0432.CCR-08-0197
pubmed: 18765544
Willoughby JA, Sundar SN, Cheung M, Tin AS, Modiano J, Firestone GL et al (2009) Artemisinin blocks prostate cancer growth and cell cycle progression by disrupting Sp1 interactions with the cyclin-dependent kinase-4 (CDK4) promoter and inhibiting CDK4 gene expression. J Biol Chem 284(4):2203–2213. https://doi.org/10.1074/jbc.M804491200
doi: 10.1074/jbc.M804491200
pubmed: 19017637
pmcid: 2629082
Steinbrück G, Pereira I, Efferth T et al (2010) Effects of artesunate on cytokinesis and G2/M cell cycle progression of tumour cells and budding yeast. Cancer Genom Proteom 7(6):337–346
Wang SJ, Gao Y, Chen H, Kong R, Jiang HC, Pan SH, Sun B et al (2010) Dihydroartemisinin inactivates NF-??B and potentiates the anti-tumor effect of gemcitabine on pancreatic cancer both in vitro and in vivo. Cancer Lett 293(1):99–108. https://doi.org/10.1016/j.canlet.2010.01.001
doi: 10.1016/j.canlet.2010.01.001
pubmed: 20137856
K Liao, J Li, Z Wang et al (2014) Dihydroartemisinin inhibits cell proliferation via AKT/GSK3β/cyclinD1 pathway and induces apoptosis in A549 lung cancer cells. Int J Clin Exp Pathol 7(12):8684–8691. Retrieved from www.ijcep.com
Liao K, Li J, Wang Z et al (2014) Dihydroartemisinin inhibits cell proliferation via AKT/GSK3β/cyclinD1 pathway and induces apoptosis in A549 lung cancer cells. Int J Clin Exp Pathol 7(12):8684–8691
pubmed: 25674233
pmcid: 4314032
Xu Q, Li Z-X, Peng H-Q, Sun Z-W, Cheng R-L, Ye Z-M, Li W-X (2011) Artesunate inhibits growth and induces apoptosis in human osteosarcoma HOS cell line in vitro and in vivo. J Zhejiang Univ Sci B 12(4):247–255
pubmed: 21462379
pmcid: 3072588
Ma H, Yao Q, Zhang AM, Lin S, Wang XX, Wu L, Chen ZT et al (2011) The effects of artesunate on the expression of EGFR and ABCG2 in A549 human lung cancer cells and a xenograft model. Molecules 16(12):10556–10569. https://doi.org/10.3390/molecules161210556
doi: 10.3390/molecules161210556
pubmed: 22183882
pmcid: 6264700
Du W, Pang C, Xue Y, Zhang Q, Wei X et al (2015) Dihydroartemisinin inhibits the Raf/ERK/MEK and PI3K/AKT pathways in glioma cells. Oncol Lett. https://doi.org/10.3892/ol.2015.3699
doi: 10.3892/ol.2015.3699
pubmed: 26893724
pmcid: 4734230
Zhang J, Ling G, Xia Z, Fengyun D, Liqun L, Zuowang C, Yinghua X, Jiyong L, Qi X, Liu Ju et al (2016) Dihydroartemisinin induces endothelial cell anoikis through the activation of the JNK signaling pathway. Oncol Lett 12:1896–1900
pubmed: 27602117
pmcid: 4998146
Zhao X, Zhong H, Wang R, Liu D, Waxman S, Zhao L, Jing Y et al (2015) Dihydroartemisinin and its derivative induce apoptosis in acute myeloid leukemia through Noxa-mediated pathway requiring iron and endoperoxide moiety. Oncotarget 6(8):5582–5596
pubmed: 25714024
pmcid: 4467388
Dong F (2014) Dihydroartemisinin targets VEGFR2 via the NF-κB pathway in endothelial cells to inhibit angiogenesis. Cancer Biol Ther 15(11):1479–1488
pubmed: 25482945
pmcid: 4623302
Hwang YP, Yun HJ, Kim HG, Han EH, Lee GW, Jeong HG et al (2010) Suppression of PMA-induced tumor cell invasion by dihydroartemisinin via inhibition of PKCα/Raf/MAPKs and NF-κB/AP-1-dependent mechanisms. Biochem Pharmacol 79(12):1714–1726
pubmed: 20152819
Aung W, Sogawa C, Furukawa T, Saga T et al (2011) Anticancer effect of dihydroartemisinin (DHA) in a pancreatic tumor model evaluated by conventional methods and optical imaging. Anticancer Res 31:1549–1558
pubmed: 21617209
He Q, Jingxue S, Xiao-Ling S, Jie A, Hong S, Lu W, Ying-Jie H, Qing S, Lin-Chun F, Saeed SM, Ying H et al (2010) Dihydroartemisinin upregulates death receptor 5 expression and cooperates with TRAIL to induce apoptosis in human prostate cancer cells. Cancer Biol Ther 9(10):819–824
pubmed: 20224297
Mao H (2013) Involvement of the mitochondrial pathway and Bim/Bcl-2 balance in dihydroartemisinin-induced apoptosis in human breast cancer in vitro. Int J Mol Med 31(1):213–218
pubmed: 23138847
Wang JX, Tang W, Shi LP, Wan J, Zhou R, Ni J, Fu YF, Yang YF, Li Y, Zuo JP et al (2007) Investigation of the immunosuppressive activity of artemether on T-cell activation and proliferation. Br J Pharmacol 150:652–661
pubmed: 17262016
pmcid: 2189761
Wu ZP, Gao CW, Wu YG, Zhu QS, Chen Y, Liu X, Liu C et al (2009) Inhibitive effect of artemether on tumor growth and angiogenesis in the rat C6 orthotopic brain gliomas model. Integr Cancer Ther 8:88–92
pubmed: 19174507
Jiao Y, Tong J (2007) Dihydroartemisinin is an inhibitor of ovarian cancer cell growth. Acta Pharmacol Sin 28(7):1045–1056
pubmed: 17588342
Cheng R, Li C, Li C, Wei L, Li L, Zhang Y, Gao G et al (2013) The artemisinin derivative artesunate inhibits corneal neovascularization by inducing ROS-dependent apoptosis in vascular endothelial cells. Invest Ophthalmol Vis Sci 54(5):3400–3409
pubmed: 23611999
pmcid: 5963000
Yang ND, Shi-Hao T, Shukie N, Yin S, Jing Z, Kevin S, Wei T, Wai-Shiu FW, Han-Ming S (2014) Artesunate induces cell death in human cancer cells via enhancing lysosomal function and lysosomal degradation of ferritin. J Biol Chem 289(48):33425–33441
pubmed: 25305013
pmcid: 4246098
Chen H, Shi L, Yang X, Li S, Guo X, Pan L et al (2010) Artesunate inhibiting angiogenesis induced by human myeloma RPMI8226 cells. Int J Hematol 92(4):587–597. https://doi.org/10.1007/s12185-010-0697-3
doi: 10.1007/s12185-010-0697-3
pubmed: 20945119
Chen H, Sun B, Wang S, Pan S, Gao Y, Bai X, Xue D et al (2010) Growth inhibitory effects of dihydroartemisinin on pancreatic cancer cells: involvement of cell cycle arrest and inactivation of nuclear factor-kappaB. J Cancer Res Clin Oncol 136(6):897–903
pubmed: 19941148
Jia G, Rui K, Zhi-Bin M, Bing H, Yong-Wei W, Shang-Ha P, Ying-Hua L, Bei S et al (2014) The activation of c-Jun NH2-terminal kinase is required for dihydroartemisinin-induced autophagy in pancreatic cancer cells. J Exp Clin Cancer Res 33:8–15
pubmed: 24438216
pmcid: 3901759
Thomas S, Quinn BA, Das SK, Dash R, Emdad L, Dasgupta S et al (2013) Targeting the Bcl-2 family for cancer therapy. Exp Opin Ther Targets 17:61–75
Chen Y, Zhang D, Liao Z et al (2015) Anti-oxidant polydatin (piceid) protects against substantia nigral motor degeneration in multiple rodent models of parkinson’s disease. Mol Neurodegener 10:4
pubmed: 26013581
pmcid: 4506434
Morrissey C, Gallis B, Solazzi JW, Kim BJ, Gulati R, Vakar-Lopez F, Sasaki T (2010) Effect of artemisinin derivatives on apoptosis and cell cycle in prostate cancer cells. Anticancer Drugs 21(4):423
pubmed: 20130467
pmcid: 2953769
Mizushima N, Levine B, Cuervo AM, Klionsky DJ et al (2008) Autophagy fights disease through cellular self-digestion. Nature 451(7182):1069–1075
pubmed: 18305538
pmcid: 2670399
Chen SS, Hu W, Wang Z, Lou XE, Zhou HJ et al (2015) p8 attenuates the apoptosis induced by dihydroartemisinin in cancer cells through promoting autophagy. Cancer Biol Ther. https://doi.org/10.1080/15384047.2015.1026477
doi: 10.1080/15384047.2015.1026477
pubmed: 26671532
pmcid: 4848005
Galluzzi L, Pietrocola F, Bravo-San Pedro JM, Amaravadi RK, Baehrecke EH, Cecconi F, Kroemer G et al (2015) Autophagy in malignant transformation and cancer progression. EMBO J 34(7):856–880. https://doi.org/10.15252/embj.201490784
doi: 10.15252/embj.201490784
pubmed: 25712477
pmcid: 4388596
Chen K, Shou L-M, Lin F, Duan W-M, Wu M-Y, Xie X, Tao M et al (2014) Artesunate induces G2/M cell cycle arrest through autophagy induction in breast cancer cells. Anticancer Drugs 25:652–662
pubmed: 24518199
Gao M, Monian P, Pan Q, Zhang W, Xiang J, Jiang X et al (2016) Ferroptosis is an autophagic cell death process. Cell Res 26(9):1021–1032. https://doi.org/10.1038/cr.2016.95
doi: 10.1038/cr.2016.95
pubmed: 27514700
pmcid: 5034113
Li Z (2016) Artemisinin and its derivatives as a repurposing anticancer agent: what else do we need to do? Molecules 21(10):1331–1339
pmcid: 6272993
Wong YK, He Y, Wang J, Xu C, Kalesh KA, Shen H, Wong WSF et al (2017) Artemisinin as an anticancer drug: recent advances in target profiling and mechanisms of action. Med Res Rev 2017(37):1492–1517. https://doi.org/10.1002/med.21446
doi: 10.1002/med.21446
Giuliano S, Pagès G (2013) Mechanisms of resistance to anti-angiogenesis therapies. Biochimie 95(6):1110–1119. https://doi.org/10.1016/j.biochi.2013.03.002
doi: 10.1016/j.biochi.2013.03.002
pubmed: 23507428
Wang SJ, Sun B, Cheng ZX, Zhou HX, Gao Y, Kong R, Bai XW et al (2011) Dihydroartemisinin inhibits angiogenesis in pancreatic cancer by targeting the NF-??B pathway. Cancer Chemother Pharmacol 68(6):1421–1430. https://doi.org/10.1007/s00280-011-1643-7
doi: 10.1007/s00280-011-1643-7
pubmed: 21479633
Boyeva SA, Brezhneva TA, Maltseva AA, Buzlama AV, Slivkin AI (2007) Saponins of the Polemonium caeruleum L. and Beta vulgaris L. plants. The features of obtaining, the comparative assessment of the hypoglycemic activity. Proc Voronezh State Univ Chem Biol Pharm 1:139–141
Cavallo F, De Giovanni C, Nanni P, Forni G, Lollini P-L (2011) 2011: the immune hallmarks of cancer. Cancer Immunol Immunother 60(3):319–326
pubmed: 21267721
pmcid: 3042096
Efferth T, Albini A, Pfeffer U et al (2006) Microarray expression profiles of angiogenesis-related genes predicttumor cell response to artemisinins. Pharmacogenom J 6:269–278
Martinez-Outschoorn UE, Peiris-Pagés M, Pestell RG, Sotgia F, Lisanti MP et al (2017) Cancer metabolism: a therapeutic perspective. Nat Rev Clin Oncol 14(1):11–31. https://doi.org/10.1038/nrclinonc.2016.60
doi: 10.1038/nrclinonc.2016.60
pubmed: 27141887
Mi Y, Geng G, Zou Z, Gao J, Luo X, Liu Y et al (2015) Dihydroartemisinin inhibits glucose uptake and cooperates with glycolysis inhibitor to induce apoptosis in non-small cell lung carcinoma cells. PLoS ONE 10(3):1–21. https://doi.org/10.1371/journal.pone.0120426
doi: 10.1371/journal.pone.0120426
Ravindra KC, Ho WE, Cheng C, Godoy LC, Wishnok JS, Ong CN, Wong WS, Wogan GN, Tannenbaum SR et al (2015) Untargeted proteomics and systems-based mechanistic investigation of artesunate in human bronchial epithelial cells. Chem Res Toxicol 28(10):1903–1913
pubmed: 26340163
pmcid: 5480315
Zhou Y, Weichao L, Xiao Y et al (2016) Profiling of Multiple Targets of Artemisinin Activated by Hemin in Cancer Cell Proteome. ACS Chem Biol 11:882–888. https://doi.org/10.1021/acschembio.5b01043
doi: 10.1021/acschembio.5b01043
pubmed: 26854499
Li Y (2012) Qinghaosu (artemisinin): chemistry and pharmacology. Acta Pharmacol Sin 33:1141–1146. https://doi.org/10.1038/aps.2012.104
doi: 10.1038/aps.2012.104
pubmed: 22922345
pmcid: 4003104
Ho WE, Peh HY, Chan TK, Wong WS et al (2014) Artemisinin: pharmacological actions beyond anti-malarial. Pharmacol Ther 142:126–139. https://doi.org/10.1016/j.pharmthera.2013.12.001
doi: 10.1016/j.pharmthera.2013.12.001
pubmed: 24316259
Crespo-Ortiz MP, Wei MQ (2012) Antitumor activity of artemisinin and its derivatives: from a well-known antimalarial agent to a potential anticancer drug. J Biomed Biotechnol 2012:247597. https://doi.org/10.1155/2012/247597
doi: 10.1155/2012/247597
pubmed: 22174561
Chaturvedi D, Goswami A, Saikia PP, Barua NC, Rao PG et al (2010) Artemisinin and its derivatives: a novel class of anti-malarial and anti-cancer agents. Chem Soc Rev 39(2):435–454
pubmed: 20111769
Efferth T (2006) Molecular pharmacology and pharmacogenomics of artemisinin and its derivatives in cancer cells. Curr Drug Targets 7:407–421
pubmed: 16611029
Reichert S, Reinboldt V, Hehlgans S, Efferth T, Rodel C, Rodel F et al (2012) A radiosensitizing effect of artesunate in glioblastoma cells is associated with a diminished expression of the inhibitor of apoptosis protein survivin. Radiother Oncol 103:394–401. https://doi.org/10.1016/j.radonc.2012.03.018
doi: 10.1016/j.radonc.2012.03.018
pubmed: 22560712
Michaelis M (2010) Anti-cancer effects of artesunate in a panel of chemoresistant neuroblastoma cell lines. Biochem Pharmacol 79(2):130–136
pubmed: 19698702
Efferth T, Merling A, Krammer PH, Li-Weber M et al (2007) Artesunate induces ROS-mediated apoptosis in doxorubicin-resistant T leukemia cells. PLoS ONE 2(8):693
Hamacher-Brady A, Stein HA, Turschner S, Toegel I, Mora R, Jennewein N, Efferth T, Eils R, Brady NR et al (2011) Artesunate activates mitochondrial apoptosis in breast cancer cells via iron-catalyzed lysosomal reactive oxygen species production. J Biol Chem 286(8):6587–6601
pubmed: 21149439
Zeng QP, Zhang PZ (2011) Artesunate mitigates proliferation of tumor cells by alkylating heme-harboring nitric oxide synthase. Nitric Oxide 24(2):110–112
pubmed: 21168521
Du JH, Zhang HD, Ma ZJ, Ji KM et al (2010) Artesunate induces oncosis-like cell death in vitro and has antitumor activity against pancreatic cancer xenografts in vivo. Cancer Chemother Pharmacol 65(5):895–902
pubmed: 19690861
Anfosso L, Efferth T, Albini A, Pfeffer U et al (2006) Microarray expression profiles of angiogenesis-related genes predict tumor cell response to artemisinins. Pharmacogenom J 6:269–278
Lai HC, Singh NP, Sasaki T et al (2013) Development of artemisinin compounds for cancer treatment. Invest New Drugs 31(1):230–246
pubmed: 22935909
Li LN, Zhang HD, Yuan SJ, Tian ZY, Wang L, Sun ZX et al (2007) Artesunate attenuates the growth of human colorectal carcinoma and inhibits hyperactive Wnt/β-catenin pathway. Int J Cancer 121(6):1360–1365
pubmed: 17520675
Eling N, Reuter L, Hazin J, Hamacher-Brady A, Brady NR et al (2015) Identification of artesunate as a specific activator of ferroptosis in pancreatic cancer cells. Oncoscience 2(5):517–532
pubmed: 26097885
pmcid: 4468338
Chen HH, Zhou HJ, Fang X et al (2003) Inhibition of human cancer cell line growth and human umbilical vein endothelial cell angiogenesis by artemisinin derivatives in vitro. Pharmacol Res 48(3):231–236
pubmed: 12860439
Zhou HJ, Wang WQ, Wu GD, Lee J, Li A et al (2007) Artesunate inhibits angiogenesis and downregulates vascular endothelial growth factor expression in chronic myeloid leukemia K562 cells. Vascul Pharmacol 47(2):131–138
pubmed: 17581794
Youns M, Efferth T, Reichling J, Fellenberg K, Bauer A, Hoheisel JD et al (2009) Gene expression profiling identifies novel key players involved in the cytotoxic effect of Artesunate on pancreatic cancer cells. Biochem Pharmacol 78:273–283
pubmed: 19393226
Rasheed SAK, Efferth T, Asangani IA, Allgayer H et al (2010) First evidence that the antimalarial drug artesunate inhibits invasion and in vivo metastasis in lung cancer by targeting essential extracellular proteases. Int J Cancer 127:1475–1485
pubmed: 20232396
Li LN, Zhang HD, Yuan SJ, Yang DX, Wang L, Sun ZX et al (2008) Differential sensitivity of colorectal cancer cell lines to artesunate is associated with expression of beta-catenin and E-cadherin. Eur J Pharmacol 588(1):1–8
pubmed: 18448095
Lai H, Nakase I, Lacoste E, Singh NP, Sasaki T et al (2009) Artemisinin-transferrin conjugate retards growth of breast tumors in the rat. Anticancer Res 29(10):3807–3810
pubmed: 19846912
Nakase I, Gallis B, Takatani-Nakase T, Oh S, Lacoste E, Singh NP, Goodlett DR, Tanaka S, Futaki S, Lai H, Sasaki T et al (2009) Transferrin receptor-dependent cytotoxicity of artemisinin–transferrin conjugates on prostate cancer cells and induction of apoptosis. Cancer Lett 274(2):290–298
pubmed: 19006645
Nakase I, Lai H, Singh NP, Sasaki T et al (2008) Anticancer properties of artemisinin derivatives and their targeted delivery by transferrin conjugation. Int J Pharm 354:28–33
pubmed: 17942255
Singh NP, Verma K (2002) Case report of a laryngeal squamous cell carcinoma treated with artesunate. Arch Oncol 10(4):279–280
Berger TG, Dieckmann D, Efferth T, Schultz ES, Funk JO, Baur A, Schuler G et al (2005) Artesunate in the treatment of metastatic uveal melanoma-first experiences. Oncol Rep 14:1599–1604
pubmed: 16273263
Zhang Z, Yu SQ, Miao LY, Huang XY, Zhang XP, Zhu YP, Xia XH, Li DQ et al (2008) Artesunate combined with vinorelbine plus cisplatin in treatment of advanced non-small cell lung cancer: a randomized controlled trial. Zhong Xi Yi Jie He Xue Bao = J Chin Integr Med 6(2):134–138
Lu JJ, Meng LH, Shankavaram UT, Zhu CH, Tong LJ, Chen G, Lin LP, Weinstein JN, Ding J et al (2010) Dihydroartemisinin accelerates c-MYC oncoprotein degradation and induces apoptosis in c-MYC-overexpressing tumor cells. Biochem Pharmacol 80(1):22–30
pubmed: 20206143
Lu YY, Chen TS, Qu JL, Pan WL, Sun L, Wei XB et al (2009) Dihydroartemisinin (DHA) induces caspase-3-dependent apoptosis in human lung adenocarcinoma ASTC-a-1 cells. J Biomed Sci 16:16–20
pubmed: 19272183
pmcid: 2653522
Lu YY, Chen TS, Wang XP, Qu JL, Chen M et al (2010) The JNK inhibitor SP600125 enhances dihydroartemisinin-induced apoptosis by accelerating Bax translocation into mitochondria in human lung adenocarcinoma cells. FEBS Lett 584:4019–4026
pubmed: 20709060
Riganti C, Doublier S, Viarisio D, Miraglia E, Pescarmona G, Ghigo D et al (2009) Artemisinin induces doxorubicin resistance in human colon cancer cells via calcium-dependent activation of HIF-1αand P-glycoprotein overexpression. Br J Pharmacol 156:1054–1066
pubmed: 19298255
pmcid: 2697684
D’Alessandro S, Basilico N, Corbett Y, Scaccabarozzi D, Omodeo-Sale F, Saresella M, Marventano I, Vaillant M, Olliaro P, Taramelli D et al (2011) Hypoxia modulates the effect of dihydroartemisinin on endothelial cells. Biochem Pharmacol 82:476–484
pubmed: 21684264
Zhang J, Li L, Liu X, Wang Y, Zhao D et al (2012) Study on chemical constituents of Artemisia sphaerocephala. China J Chin Materia Med 37(2):238–242
Zhang CZ, Zhang H, Yun J, Chen GG, Lai PB et al (2012) Dihydroartemisinin exhibits antitumor activity toward hepatocellular carcinoma in vitro and in vivo. Biochem Pharmacol 83(9):1278–1289
pubmed: 22342732
Wang SJ (2010) Dihydroartemisinin inactivates NF-??B and potentiates the anti-tumor effect of gemcitabine on pancreatic cancer both in vitro and in vivo. Cancer Lett 293(1):99–108
pubmed: 20137856
Wang SJ (2011) Dihydroartemisinin inhibits angiogenesis in pancreatic cancer by targeting the NF-??B pathway. Cancer Chemother Pharmacol 68(6):1421–1430
pubmed: 21479633
Wu XL, Zhang WG, Shi XM, An P, Sun WS, Qiao CL, Wang Z et al (2011) Effect of artemisinin on the expressions of GRalpha mRNA, GRbeta mRNA and P300/CBP protein in lupus nephritis mice. J Chin Med Mater 17(4):277–282
Wang J, Zhang C-J, Chia WN et al (2015) Haem-activated promiscuous targeting of artemisinin in Plasmodium falciparum. Nat Commun 6:10111
pubmed: 26694030
D’Alessandro S, Gelati M, Basilico N, Parati EA, Haynes RK, Taramelli D et al (2007) Differential effects on angiogenesis of two antimalarial compounds, dihydroartemisinin and artemisone: implications for embryotoxicity. Toxicology 241(1):66–74
pubmed: 17897768
Wei-Ling X, Pei-Hui Y, Zeng X, Ji-Ye C et al (2009) Effect of 4-(12-dihydroartemisininoxy) benzoic acid hydrazide transferrin tagged drug on human breast cancer cells. Chin J Anal Chem 37(5):671–675
Singh NP, Panwar VK (2006) Case report of a pituitary macroadenoma treated with artemether. Integr Cancer Ther 5:391–394
pubmed: 17101767
Farsam V, Hassan ZM, Zavaran-Hosseini A, Noori S, Mahdavi M, Ranjbar M et al (2011) Antitumor and immunomodulatory properties of artemether and its ability to reduce CD4+ CD25+ FoxP3+ T reg cells in vivo. Int Immunopharmacol 11:1802–1808
pubmed: 21824530
Alcântara DDFÁ, Ribeiro HF, Cardoso PCS, Araújo TMT, Burbano RR, Guimarães AC, Khayat AS, Oliveira BM et al (2013) In vitro evaluation of the cytotoxic and genotoxic effects of artemether, an antimalarial drug, in a gastric cancer cell line (PG100). J Appl Toxicol 33:151–156
pubmed: 21953315
Zhao Y, Jiang W, Li B, Yao Q, Dong J, Chen Y, Pan X, Li J, Zheng J, Pang X et al (2011) Artesunate enhances radiosensitivity of human non-small cell lung cancer A549 cells via increasing no production to induce cell cycle arrest at G 2/M phase. Int Immunopharmacol 11:2039–2046
pubmed: 21907831
Efferth T, Oesch F (2004) Oxidative stress response of tumor cells: microarray-based comparison between artemisinins and anthracyclines. Biochem Pharmacol 68:3–10
pubmed: 15183112
Luthria DL (2006) Significance of sample preparation in developing analytical methodologies for accurate estimation of bioactive compounds in functional foods. J Sci Food Agric 86(14):2266–2272
Castellano G, Tena J, Torrens F et al (2012) Classification of phenolic compounds by chemical structural indicators and its relation to antioxidant properties of posidonia oceanica (L.) Delile. Environment 2:6–9
Ferreira JF, Luthria DL, Sasaki T, Heyerick A et al (2010) Flavonoids from Artemisia annua L. as antioxidants and their potential synergism with artemisinin against malaria and cancer. Molecules 15(5):3135–3170
pubmed: 20657468
pmcid: 6263261
Croteau R, Kutchan T, Lewis N et al (2000) Natural products (secondary metabolites). Biochem Mol Biol Plants 24:1250–1319
Debeaujon I, Peeters AJ, Léon-Kloosterziel KM, Koornneef M et al (2001) The TRANSPARENT TESTA12 gene of Arabidopsis encodes a multidrug secondary transporter-like protein required for flavonoid sequestration in vacuoles of the seed coat endothelium. Plant Cell 13(4):853–871
pubmed: 11283341
pmcid: 135529
Kitamura S (2006) Transport of flavonoids: from cytosolic synthesis to vacuolar accumulation. The science of flavonoids. Springer, Cham, pp 123–146
Grassi D, Desideri G, Ferri C et al (2010) Flavonoids: antioxidants against atherosclerosis. Nutrients 2:889–902
pubmed: 22254061
pmcid: 3257706
Middleton JR (1998) Effect of plant flavonoids on immune and inflammatory cell function. Flavonoids in the living system. Springer, Cham, pp 175–182
Falcone Ferreyra ML, Rius S, Casati P et al (2012) Flavonoids: biosynthesis, biological functions, and biotechnological applications. Front Plant Sci 3:222
pubmed: 23060891
pmcid: 3460232
Aberham A, Cicek SS, Schneider P, Stuppner H et al (2010) Analysis of sesquiterpene lactones, lignans, and flavonoids in wormwood (Artemisia absinthium L.) using high-performance liquid chromatography (HPLC)—mass spectrometry, reversed phase HPLC, and HPLC—solid phase extraction—nuclear magnetic resonance. J Agric Food Chem 58(20):10817–10823
pubmed: 20886883
Singh R, Verma PK, Singh G et al (2012) Total phenolic, flavonoids and tannin contents in different extracts of Artemisia absinthium. J Intercult Ethnopharmacol 1(2):101–104
Hajdú Z, Martins A, Orbán-Gyapai O, Forgo P, Jedlinszki N, Máthé I, Hohmann J et al (2014) Xanthine oxidase-inhibitory activity and antioxidant properties of the methanol extract and flavonoids of Artemisia asiatica. Rec Nat Prod 8(3):299
Qnais E, Raad D, Bseiso Y et al (2014) Analgesic and anti-inflammatory effects of an extract and flavonoids from Artemisia herba-alba and their mechanisms of action. Neurophysiology 46(3):238–246
Suresh J, Ahuja J, Paramakrishnan N, Sebastian M et al (2012) Total phenolic and total flavonoids content of aerial parts of Artemisia abrotanum Linn. and A. pallens wall. Anal Chem Lett 2(3):186–191
Xiao M, Luo D, Ke Z, Ye J, Tu PF (2014) A novel polyacetylene from the aerial parts of Artemisia lactiflora. Phytochem Lett 8:52–54
Mabeza GF, Loyevsky M, Gordeuk VR, Weiss G et al (1999) Iron chelation therapy for malaria: a review. Pharmacol Ther 81(1):53–75
pubmed: 10051178
Lai H, Singh NP (1995) Selective cancer cell cytotoxicity from exposure to dihydroartemisinin and holotransferrin. Cancer Lett 91(1):41–46
pubmed: 7750093
Moore JC, Lai H, Li JR, Ren RL, McDougall JA, Singh NP, Chou CK et al (1995) Oral administration of dihydroartemisinin and ferrous sulfate retarded implanted fibrosarcoma growth in the rat. Cancer Lett 98(1):83–87
pubmed: 8529210
Li XY, Zhao Y, Sun MG, Shi JF, Ju RJ, Zhang CX, Lu WL et al (2014) Multifunctional liposomes loaded with paclitaxel and artemether for treatment of invasive brain glioma. Biomaterials 35(21):5591–5604. https://doi.org/10.1016/j.biomaterials.2014.03.049
doi: 10.1016/j.biomaterials.2014.03.049
pubmed: 24726749
Li P, Yang S, Dou M, Chen Y, Zhang J, Zhao X et al (2014) Synergic effects of artemisinin and resveratrol in cancer cells. J Cancer Res Clin Oncol 140(12):2065–2075
pubmed: 25048878
Dilshad E, Zafar S, Ismail H, Waheed MT, Cusido RM, Palazon J, Mirza B (2016) Effect of rol genes on polyphenols biosynthesis in Artemisia annua and their effect on antioxidant and cytotoxic potential of the plant. Appl Biochem Biotechnol 179(8):1456–1468
pubmed: 27085357
Dilshad E, Ismail H, Khan MA, Cusido RM, Mirza B (2020) Metabolite profiling of Artemisia carvifolia Buch transgenic plants and estimation of their anticancer and antidiabetic potential. Biocatal Agric Biotechnol 24:101539
Tolomeo M, Grimaudo S, Di Cristina A, Roberti M, Pizzirani D, Meli M, Dusonchet L, Gebbia N, Abbadessa V, Crosta L et al (2005) Pterostilbene and 3′-hydroxypterostilbene are effective apoptosis-inducing agents in MDR and BCR-ABL-expressing leukemia cells. Int J Biochem Cell Biol 37(8):1709–1726
pubmed: 15878840
Yeon J, Raj C, Thapa K, Soon C, Jong Y, Kim O et al (2016) Nanoparticle-based combination drug delivery systems for synergistic cancer treatment. J Pharm Investig. https://doi.org/10.1007/s40005-016-0252-1
doi: 10.1007/s40005-016-0252-1
Ochiuz L, Grigoras C, Popa M, Stoleriu I, Munteanu C, Timofte D, Grigoras AG et al (2016) Alendronate-loaded modified drug delivery lipid particles intended for improved oral and topical administration. Molecules 21(7):858. https://doi.org/10.3390/molecules21070858
doi: 10.3390/molecules21070858
pmcid: 6272979
Gharib A, Faezizadeh Z, Mesbah-Namin SA, Saravani R et al (2014) Preparation, characterization and in vitro efficacy of magnetic nanoliposomes containing the artemisinin and transferrin. Daru 22(1):44–50. https://doi.org/10.1186/2008-2231-22-44
doi: 10.1186/2008-2231-22-44
pubmed: 24887240
pmcid: 4053270
Wu GS (2013) Synergistic anti-cancer activity of the combination of dihydroartemisinin and doxorubicin in breast cancer cells. Pharmacol Rep 65(2):453–459
pubmed: 23744430
Eltayeb SE, Su Z, Xiao Y, Ping Q et al (2016) Antitumor activity of transferrin-modified- artemether lipid nanospheres in cancer cell lines. J Drug Deliv Sci Technol 31:118–129. https://doi.org/10.1016/j.jddst.2015.12.003
doi: 10.1016/j.jddst.2015.12.003
Nguyen DX, Massague J (2014) Genetic determinants of cancer metastasis. Nat Rev Genet 8:341–352
Jiang W, Huang Y, Wang J, Yu X, Zhang L et al (2013) The synergistic anticancer effect of artesunate combined with allicin in osteosarcoma cell line in vitro and in vivo. Asian Pac J Cancer Prev 14:4615–4619
pubmed: 24083713
Krusche B, Arend J, Efferth T et al (2013) Synergistic inhibition of angiogenesis by artesunate and captopril in vitro and in vivo. Evid Based Complement Altern Med. https://doi.org/10.1155/2013/454783
doi: 10.1155/2013/454783